Latest Articles

A Tireless Advocate for Children With Cancer and a Beacon of Hope
BY JULIE BLATT, MD
An Extraordinary Healer essay honoring Diana Gordon, RN, MSN, CNCP, CPON [ University of North Carolina, Division of Pediatric Hematology Oncology in Chapel Hill, North Carolina]
Study Suggests BRCA1 Carriers Should Avoid Delaying Pregnancy
BY ELLIE LEICK
According to a recent study, women with the BRCA1 mutation should not delay their pregnancies because their fertility may quickly decline once they enter their 30s. 
Connecting the Dots: Vitiligo Can Predict Immunotherapy Response in Melanoma
BY HEATHER MILLAR

 

Why is the development of vitiligo a predictor of good response in patients taking immunotherapy for melanoma, and what can scientists learn from this? 

Wild Card: Treating Triple Wild-Type Melanoma
BY SONYA COLLINS

 

Triple wild-type melanoma may not respond to approved targeted drugs, but immunotherapy can be an excellent option. 

Perspective Taking
BY TONYA MARIE PAN, MA, MS
The New Front Line in Melanoma: Immunotherapy OR Targeted Agents?
BY ANITA T. SHAFFER

In the fast-moving world of melanoma treatment, new therapeutic options for patients with metastatic disease are emerging faster than oncology researchers can establish guidelines for their optimal clinical use. That is raising questions about which should be the firstline choice in metastatic melanoma — targeted drugs or immunotherapy — and how these drugs should be sequenced. 

Refreshing Your Memory: Easing the Effects of Chemobrain Through Training
BY CONNIE CARSON

Speech pathologists can help ease “chemobrain” through cognition training, and by teaching patients to compensate for deficits in memory or skills.

Adjusting to Cancer's
BY STEPHANIE J. HAMMONDS
Melanoma: Fertile Territory for the Development of New Treatments
BY ARLENE WEINTRAUB

In clinical trials, melanoma remains a ripe discovery ground for the application and combination of immunotherapies and targeted drugs.

$auto_registration$